Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug ABBV-932 aims to ease bipolar depression in 26-Week trial

NCT ID NCT07220460

Symptom relief Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing the safety and tolerability of an experimental drug called ABBV-932 for people with bipolar I or II disorder who are currently in a depressive episode. About 200 adults will take the drug as capsules for 26 weeks, with regular check-ups and tests to monitor side effects and mood changes. The goal is to see if ABBV-932 can help manage depressive symptoms safely over the long term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Body Mass Index (BMI) \>= 18.0 to \<= 40.0 kg/m\^2, inclusive. * Participants who currently meet the Diagnostic and Statistical Manual of Mental Disorders treatment (DSM-5-TR) criteria for bipolar I or II disorder without psychotic features based on the Mini International Neuropsychiatric Interview (MINI 7.0.2), currently experiencing a depressive episode of at least 4 weeks and not exceeding 12 months. * Normal physical examination findings, clinical laboratory test results, vital signs, and 12-lead ECG results at screening or abnormal results that are judged not clinically significant by the investigator and documented as such in the eCRF * Participant with the following psychiatric history: * No history of psychiatric hospitalization (inpatient or intensive outpatient) in the past 3 months prior to screening. * No lifetime history of schizophrenia, other psychotic disorders, dissociative disorders, or neurocognitive disorders. * No history of moderate or severe substance use disorder (except nicotine) in the past 6 months prior to screening. * History of stable psychiatric comorbidities (e.g., PTSD, OCD) may be included provided these conditions have not required intervention with a prohibited medication within the past 12 months prior to Screening. Exclusion Criteria: * A total score greater than 12 on the Young Mania Rating Scale (YMRS) at baseline. * History of an allergic reaction or significant sensitivity to constituents of the study drug (and its excipients) and/or other products in the same class. * A concurrent medical condition that might interfere with the conduct of the study, confound the interpretation of the study results, or endanger the subject's well-being. This includes any unstable condition, history or evidence of malignancy (other than treated basal or squamous cell carcinoma), or any significant hematologic, endocrine, cardiovascular, respiratory, renal impairment or disease (e.g., participants with eGFR \< 30 mL/min), hepatic (including history of severe hepatic impairment), gastrointestinal, or neurological disorder. If there is a history of such disease (except malignancy), but the condition has been stable for more than 1 year, does not require treatment with prohibited medications, and is judged by the investigator not to interfere with participation in the study, the subject may be included.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bipolar I disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bipolar disorder bipolar I disorder bipolar II disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bipolar I or II disorder

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    48 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Advanced Research Center /ID# 273474

    RECRUITING

    Anaheim, California, 92805, United States

  • Alivation Research /ID# 279464

    RECRUITING

    Lincoln, Nebraska, 68526, United States

  • Alliance for Research Alliance for Wellness /ID# 273477

    RECRUITING

    Long Beach, California, 90807, United States

  • Allied Biomedical Res Inst Inc /ID# 273476

    RECRUITING

    Miami, Florida, 33155, United States

  • Apg Research /ID# 278439

    RECRUITING

    Orlando, Florida, 32803, United States

  • Arch Clinical Trials /ID# 273481

    RECRUITING

    St Louis, Missouri, 63125, United States

  • Atlanta Center for Medical Research /ID# 278827

    RECRUITING

    Atlanta, Georgia, 30331, United States

  • Axiom Research /ID# 273482

    RECRUITING

    Colton, California, 92324, United States

  • BDH Research /ID# 274677

    RECRUITING

    San Juan, 00927, Puerto Rico

  • Benchmark Research /ID# 273490

    COMPLETED

    Shreveport, Louisiana, 71101, United States

  • Bio Behavioral Health /ID# 273478

    RECRUITING

    Toms River, New Jersey, 08755, United States

  • Clinical Neuroscience Solutions Healthcare - Jacksonville /ID# 278332

    RECRUITING

    Jacksonville, Florida, 32256, United States

  • Collaborative Neuroscience Research - Garden Grove /ID# 273492

    RECRUITING

    Garden Grove, California, 92845, United States

  • Connecticut Clinical Research - Cromwell /ID# 278116

    RECRUITING

    Cromwell, Connecticut, 06416, United States

  • Core Clinical Research /ID# 273498

    RECRUITING

    Everett, Washington, 98201, United States

  • Elixia - Springfield /ID# 278446

    RECRUITING

    Springfield, Massachusetts, 01103, United States

  • Epic Medical Research - DeSoto /ID# 278045

    RECRUITING

    DeSoto, Texas, 75115, United States

  • Excell Research /ID# 273483

    RECRUITING

    Oceanside, California, 92056, United States

  • Family Psychiatry Of The Woodlands /ID# 278050

    RECRUITING

    The Woodlands, Texas, 77381, United States

  • Floridian Clinical Research - Miami Lakes /ID# 279379

    RECRUITING

    Miami Lakes, Florida, 33016, United States

  • FutureSearch Trials of Dallas /ID# 273473

    RECRUITING

    Dallas, Texas, 75231, United States

  • GMI Florida - Central Miami Medical Institute /ID# 273486

    RECRUITING

    Miami, Florida, 33125, United States

  • Health Synergy Clinical Research /ID# 279384

    RECRUITING

    West Palm Beach, Florida, 33407, United States

  • Ima Clinical Research - Manhattan /ID# 278941

    RECRUITING

    New York, New York, 10036, United States

  • Ima Clinical Research Las Vegas (SMO/Network/Consortium) /ID# 278054

    RECRUITING

    Las Vegas, Nevada, 89102, United States

  • Ima Clinical Research Phoenix (Alea) /ID# 278047

    RECRUITING

    Phoenix, Arizona, 85012, United States

  • Inland Psychiatric Medical Group /ID# 273471

    RECRUITING

    Temecula, California, 92591, United States

  • Inspira Clinical Research /ID# 274670

    RECRUITING

    San Juan, 00918-3014, Puerto Rico

  • Integrative Clinical Trials /ID# 278040

    RECRUITING

    Brooklyn, New York, 11229, United States

  • K2 Medical Research - Orlando - South Orlando Avenue /ID# 273487

    RECRUITING

    Orlando, Florida, 32751, United States

  • Lehigh Center for Clinical Research /ID# 273466

    RECRUITING

    Allentown, Pennsylvania, 18103, United States

  • MSB Neuroscience /ID# 278168

    RECRUITING

    Jackson, Mississippi, 39216-4643, United States

  • Neurobehavioral Research /ID# 273470

    RECRUITING

    Cedarhurst, New York, 11516, United States

  • New Hope Clinical Research - Inpatient unit /ID# 273468

    RECRUITING

    Charlotte, North Carolina, 28211, United States

  • Northwest Clinical Research Center /ID# 273480

    RECRUITING

    Bellevue, Washington, 98007, United States

  • Nrc Research Institute - Los Angeles /ID# 278450

    RECRUITING

    Los Angeles, California, 90015, United States

  • OSU Psychiatry Department /ID# 273495

    RECRUITING

    Columbus, Ohio, 43210, United States

  • Perceptive Pharma Research /ID# 273485

    RECRUITING

    Richmond, Texas, 77407, United States

  • Pharmasite Research, Inc. /ID# 279163

    RECRUITING

    Baltimore, Maryland, 21208, United States

  • Quest Therapeutics of Avon Lake /ID# 273484

    RECRUITING

    Avon Lake, Ohio, 44012, United States

  • Redbird Research /ID# 279475

    RECRUITING

    Las Vegas, Nevada, 89119, United States

  • Revive Research Institute - Elgin /ID# 279756

    RECRUITING

    Elgin, Illinois, 60123, United States

  • Segal Trials - West Broward Outpatient Research Site /ID# 273496

    RECRUITING

    Tamarac, Florida, 33319-4985, United States

  • Sooner Clinical Research /ID# 273491

    RECRUITING

    Oklahoma City, Oklahoma, 73116, United States

  • Summit Research Network - Portland - Northwest Vaughn Street /ID# 278084

    RECRUITING

    Portland, Oregon, 97210, United States

  • Sun Valley Research Center /ID# 273472

    RECRUITING

    Imperial, California, 92251, United States

  • Sunwise Clinical Research /ID# 278165

    RECRUITING

    Walnut Creek, California, 94596, United States

  • Synergy San Diego /ID# 278340

    RECRUITING

    Lemon Grove, California, 91945, United States

  • Trialmed /ID# 278046

    RECRUITING

    Atlanta, Georgia, 30328, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.